ARCHIVES

EGFR Inhibitor Shrinks Tumors In Phase I Study of Patients With Treatment-Resistant Mutation

This article is from The Cancer Letter archive.

Vol. 37 No. 5 | May 30, 2014

Download PDF Visit The Full Archive

Related Articles

NCI Advisory Group, Other Cancer Meetings

April 29, 1983

Adjuvant XELOX More Effective Than 5-FU/LV For Stage III Colon Cancer

January 29, 2010

NCI Must Limit Grant Payments for Now, Until Congress Approves FY03 Budget

December 6, 2002

NCAB To Monitor Virus Program; NCI Answers Zinder Report Criticisms

June 28, 1974

Craig Thompson Of Abramson Center Named President, CEO, Of Memorial Sloan-Kettering

September 3, 2010

Cell Therapeutics To Appeal FDA Decision on Pixantrone.

September 17, 2010